GP130 stimulation and the maintenance of stem cells

Trends in Biotechnology

Volumn 20, Issue 10, 2002, Pages 417-419

  Rose John, Stefan ^a  

^a UNIVERSITY OF KIEL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASES; NEUROLOGY; TUMORS;

THERAPEUTIC APPLICATIONS;

CELLS;

GLYCOPROTEIN GP 130; INTERLEUKIN 6;

BIOTECHNOLOGY;

CELL CULTURE; DIAPAUSE; DROSOPHILA; NONHUMAN; PRIORITY JOURNAL; PROTEIN FAMILY; REVIEW; STEM CELL;

ANIMALS; ANTIGENS, CD; CELL DIFFERENTIATION; CELLS, CULTURED; CULTURE MEDIA, CONDITIONED; CYTOKINE RECEPTOR GP130; CYTOKINES; GROWTH INHIBITORS; HUMANS; INTERLEUKIN-6; LEUKEMIA INHIBITORY FACTOR; LYMPHOKINES; MEMBRANE GLYCOPROTEINS; MICE; RATS; SIGNAL TRANSDUCTION; STEM CELLS; STIMULATION, CHEMICAL; TRANS-ACTIVATORS;

ARACHNIDA; HEXAPODA; MURINAE;

EID: 0036772849     PISSN: 01677799     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-7799(02)02056-5     Document Type: Review

References (21)

1. Smith A.G., et al. Inhibition of pluripotential embryonic stem cell differentiation by purified polypeptides. Nature. 336:1988;688-690.
2. Taga T., Kishimoto T. gp130 and the interleukin-6 family of cytokines. Annu. Rev. Immunol. 15:1997;797-819.
3. Rose-John S., Heinrich P.C. Soluble receptors for cytokines and growth factors: generation and biological function. Biochem. J. 300:1994;281-290.
4. Nichols J., et al. Derivation of germline competent embryonic stem cells with a combination of interleukin-6 and soluble interleukin-6 receptor. Exp. Cell Res. 215:1994;237-239.
5. Yoshida K., et al. Maintenance of the pluripotential phenotype of embryonic stem cells through direct activation of gp130 signalling pathways. Mech. Dev. 45:1994;163-171.
6. Matsuda T., et al. STAT3 activation is sufficient to maintain an undifferentiated state of mouse embryonic stem cells. EMBO J. 18:1999;4261-4269.
7. Brown S., et al. Identification of the first invertebrate interleukin JAK/STAT receptor, the Drosophila gene domeless. Curr. Biol. 11:2001;1700-1705.
8. Harrison D.A., et al. Drosophila unpaired encodes a secreted protein that activates the JAK signaling pathway. Genes Dev. 12:1988;3252-3263.
9. Kiger A.A., et al. Stem cell self-renewal specified by JAK-STAT activation in response to a support cell cue. Science. 294:2001;2542-2545.
10. Tulina N., Matunis E. Control of stem cell self-renewal in Drosophila spermatogenesis by JAK-STAT signaling. Science. 294:2001;2546-2549.
11. Ware C.B., et al. Targeted disruption of the low-affinity leukemia inhibitory factor receptor gene causes placental, skeletal, neural and metabolic defects and results in perinatal death. Development. 121:1995;1283-1299.
12. Yoshida K., et al. Targeted disruption of gp130, a common signal transducer for the interleukin 6 family of cytokines, leads to myocardial and hematological disorders. Proc. Natl. Acad. Sci. U. S. A. 93:1996;407-411.
13. Nichols J., et al. Physiological rationale for responsiveness of mouse embryonic stem cells to gp130 cytokines. Development. 128:2001;2333-2339.
14. Audet J., et al. Distinct role of gp130 activation in promoting self-renewal divisions by mitogenically stimulated murine hematopoietic cells. Proc. Natl. Acad. Sci. U. S. A. 98:2001;1757-1762.
15. Peters M., et al. Extramedullary expansion of hematopoietic progenitor cells in IL-6/sIL-6R double transgenic mice. J. Exp. Med. 185:1997;755-766.
16. Fischer M., et al. A designer cytokine with high activity on human hematopoietic progenitor cells. Nat. Biotechnol. 15:1997;142-145.
17. Bernhard H., et al. The gp130 stimulating designer cytokine Hyper-IL-6 promotes the expansion of human hematopoietic progenitor cells capable to differentiate into functional dendritic cells. Exp. Hematol. 28:2000;365-372.
18. Viswanathan S., et al. Maintenance of ES cell pluripotentiality is regulated by the number and types of gp130-mediated signaling complexes. Stem Cells. 20:2002;119-138.
19. Galun E., et al. Liver regeneration induced by a designed hIL-6/shIL-6R fusion protein reverses severe hepatocellular injury. FASEB J. 14:2000;1979-1987.
20. Hecht N., et al. Hyper-IL-6 gene therapy reverses fulminant hepatic failure. Mol. Ther. 3:2001;683-687.
21. Peters M., et al. Combined interleukin-6 and soluble interleukin-6 receptor accelerates murine liver regeneration. Gastroenterology. 119:2000;1663-1671.